Amneal Pharmaceuticals received approval for its abbreviated new drug application for the drug in six strengths — 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg — according to a Feb. 19 news release from the drugmaker.
Some common adverse reactions associated with the drug, which is used to treat certain blood cancers, include neutropenia, thrombocytopenia and leukopenia.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
